Theriva Biologics Inc (TOVX)
Theriva Biologics Inc. is a clinical-stage biotechnology company listed on the NYSE under the ticker TOVX. The company focuses on developing treatments for cancer and other diseases with significant unmet medical needs. Its pipeline includes VCN-01, an oncolytic adenovirus being studied in clinical trials for several cancers, including pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. Other programs include VCN-11 for solid tumors, SYN-004 (ribaxamase) for prevention of acute graft-versus-host disease in allogeneic hematopoietic cell transplant settings, and SYN-020, a recombinant oral enzyme formulation being evaluated for gastrointestinal and metabolic uses. Additional clinical-stage candidates include SYN-006 and SYN-007. The company has licensing and clinical trial agreements related to SYN-020 and SYN-004. Theriva Biologics is headquartered in Rockville, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-TOVX
|
$0.30
|
29.0% Upside
|
Undervalued
|
$2.50
|
989.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.5x
|
0.7x
|
35.1x
|
10.509 M
|
-205.634 K
|
26.0%
|
98.4%
|
-27.9
|
—
|
62.7%
|
